US Stem Cell Stock

US Stem Cell Equity

The The Equity of US Stem Cell (USRM) as of Aug 9, 2026 is -14.75 M USD. In the previous year, The Equity was -12.77 M USD — a change of 15.50% (lower).

Equity

-14.75 MUSD

YoY

15.50%

Last updated:

In 2026, US Stem Cell's equity was -14.75 M USD, a 15.50% increase from the -12.77 M USD equity in the previous year.

Access this data via the Eulerpool API

US Stem Cell Stock analysis

What does US Stem Cell do? US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry. US Stem Cell is one of the most popular companies on Eulerpool.

Equity Details

Analyzing US Stem Cell's Equity

US Stem Cell's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding US Stem Cell's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating US Stem Cell's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

US Stem Cell's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in US Stem Cell’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about US Stem Cell stock

The Equity of US Stem Cell is -14.75 M USD in 2026.

The Equity of US Stem Cell changed from -12.77 M USD to -14.75 M USD, representing a 15.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity US Stem Cell since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's US Stem Cell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — US Stem Cell

All Key Metrics — US Stem Cell